Skip to main content

The Foxo1-Inducible Transcriptional Repressor Zfp125 Causes Hepatic Steatosis and Hypercholesterolemia.

Citation
Fernandes, G. W., et al. “The Foxo1-Inducible Transcriptional Repressor Zfp125 Causes Hepatic Steatosis And Hypercholesterolemia.”. Cell Reports, pp. 523-534.
Center Joslin Diabetes Center
Author Gustavo W Fernandes, Barbara M L C Bocco, Tatiana L Fonseca, Elizabeth A McAninch, Sungro Jo, Lattoya J Lartey, InSug O-Sullivan, Terry G Unterman, Nailliw Z Preite, Robin M Voigt, Christopher B Forsyth, Ali Keshavarzian, Richárd Sinkó, Allison B Goldfine, Mary E Patti, Miriam O Ribeiro, Balázs Gereben, Antonio C Bianco
Keywords cholesterol, deiodinase, Hepatocytes, liver, steatosis, transcriptional repressor, triglycerides, zinc finger protein 125
Abstract

Liver-specific disruption of the type 2 deiodinase gene (Alb-D2KO) results in resistance to both diet-induced obesity and liver steatosis in mice. Here, we report that this is explained by an ∼60% reduction in liver zinc-finger protein-125 (Zfp125) expression. Zfp125 is a Foxo1-inducible transcriptional repressor that causes lipid accumulation in the AML12 mouse hepatic cell line and liver steatosis in mice by reducing liver secretion of triglycerides and hepatocyte efflux of cholesterol. Zfp125 acts by repressing 18 genes involved in lipoprotein structure, lipid binding, and transport. The ApoE promoter contains a functional Zfp125-binding element that is also present in 17 other lipid-related genes repressed by Zfp125. While liver-specific knockdown of Zfp125 causes an "Alb-D2KO-like" metabolic phenotype, liver-specific normalization of Zfp125 expression in Alb-D2KO mice rescues the phenotype, restoring normal susceptibility to diet-induced obesity, liver steatosis, and hypercholesterolemia.

Year of Publication
2018
Journal
Cell reports
Volume
22
Issue
2
Number of Pages
523-534
Date Published
12/2018
ISSN Number
2211-1247
DOI
10.1016/j.celrep.2017.12.053
Alternate Journal
Cell Rep
PMID
29320745
PMCID
PMC6474669
Download citation